Research Analysts Offer Predictions for Ionis Pharmaceuticals Inc’s FY2020 Earnings (NASDAQ:IONS)

Share on StockTwits

Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Stock analysts at Svb Leerink raised their FY2020 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued on Wednesday, November 6th. Svb Leerink analyst M. Foroohar now expects that the company will earn $0.62 per share for the year, up from their prior forecast of $0.52.

Several other analysts also recently commented on IONS. Sanford C. Bernstein raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research note on Tuesday, September 10th. TheStreet downgraded Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Thursday, August 8th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. ValuEngine downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Wells Fargo & Co increased their price objective on Ionis Pharmaceuticals from $90.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $73.45.

NASDAQ IONS opened at $57.06 on Friday. The firm has a market capitalization of $7.64 billion, a PE ratio of 19.28, a price-to-earnings-growth ratio of 15.24 and a beta of 1.90. Ionis Pharmaceuticals has a 12 month low of $48.27 and a 12 month high of $86.58. The business’s 50-day moving average price is $57.99 and its two-hundred day moving average price is $64.32. The company has a current ratio of 10.01, a quick ratio of 9.93 and a debt-to-equity ratio of 0.45.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.49. The business had revenue of $168.00 million for the quarter, compared to analyst estimates of $152.47 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. Ionis Pharmaceuticals’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.03) EPS.

In other news, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $71.52, for a total value of $1,573,440.00. Following the completion of the transaction, the chairman now directly owns 79,634 shares of the company’s stock, valued at $5,695,423.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC grew its holdings in Ionis Pharmaceuticals by 38.5% during the second quarter. Advisory Services Network LLC now owns 907 shares of the company’s stock valued at $58,000 after purchasing an additional 252 shares during the period. Daiwa Securities Group Inc. grew its holdings in Ionis Pharmaceuticals by 567.4% during the second quarter. Daiwa Securities Group Inc. now owns 5,840 shares of the company’s stock valued at $375,000 after purchasing an additional 4,965 shares during the period. Polianta Ltd bought a new position in Ionis Pharmaceuticals during the second quarter valued at $1,079,000. Pacer Advisors Inc. bought a new position in shares of Ionis Pharmaceuticals in the second quarter worth $1,307,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 5.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 616,513 shares of the company’s stock worth $39,624,000 after acquiring an additional 33,997 shares during the period. 88.89% of the stock is owned by institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Article: Capital Gains

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.